JP2006524185A - 眼球及び眼周囲疾患を治療するための組成物、ターゲット、方法、及び装置 - Google Patents

眼球及び眼周囲疾患を治療するための組成物、ターゲット、方法、及び装置 Download PDF

Info

Publication number
JP2006524185A
JP2006524185A JP2004571477A JP2004571477A JP2006524185A JP 2006524185 A JP2006524185 A JP 2006524185A JP 2004571477 A JP2004571477 A JP 2004571477A JP 2004571477 A JP2004571477 A JP 2004571477A JP 2006524185 A JP2006524185 A JP 2006524185A
Authority
JP
Japan
Prior art keywords
eye
pressure
muscle
compound
intraocular pressure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004571477A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006524185A5 (https=
Inventor
マーシオ マーク アブリュー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2006524185A publication Critical patent/JP2006524185A/ja
Publication of JP2006524185A5 publication Critical patent/JP2006524185A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Cosmetics (AREA)
JP2004571477A 2003-04-24 2003-12-08 眼球及び眼周囲疾患を治療するための組成物、ターゲット、方法、及び装置 Pending JP2006524185A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/421,956 US20040058313A1 (en) 2002-04-24 2003-04-24 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
PCT/US2003/038740 WO2004096183A1 (en) 2003-04-24 2003-12-08 Compositions, targets, methods and devices for the therapy of ocular and periocular disorders

Publications (2)

Publication Number Publication Date
JP2006524185A true JP2006524185A (ja) 2006-10-26
JP2006524185A5 JP2006524185A5 (https=) 2007-02-01

Family

ID=33415845

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004571477A Pending JP2006524185A (ja) 2003-04-24 2003-12-08 眼球及び眼周囲疾患を治療するための組成物、ターゲット、方法、及び装置

Country Status (7)

Country Link
US (2) US20040058313A1 (https=)
EP (1) EP1622589B1 (https=)
JP (1) JP2006524185A (https=)
AU (1) AU2003297684A1 (https=)
BR (1) BR0318269A (https=)
CA (2) CA2523363C (https=)
WO (1) WO2004096183A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518442A (ja) * 2013-05-15 2016-06-23 ボスティ トレーディング リミテッドＢｏｓｔｉ Ｔｒａｄｉｎｇ Ｌｔｄ． ボツリヌス神経毒を含む医薬組成物およびその使用
JP2020500938A (ja) * 2016-12-08 2020-01-16 ボロディック ゲイリー イーＢＯＲＯＤＩＣ，Ｇａｒｙ Ｅ． 黄斑変性症の新しい治療法

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040170665A1 (en) * 2000-06-02 2004-09-02 Allergan, Inc. Intravitreal botulinum toxin implant
CA2491312C (en) * 2002-07-15 2011-05-31 Alcon, Inc. Bioerodible film for ophthalmic drug delivery
US7521481B2 (en) 2003-02-27 2009-04-21 Mclaurin Joanne Methods of preventing, treating and diagnosing disorders of protein aggregation
US7220422B2 (en) * 2003-05-20 2007-05-22 Allergan, Inc. Methods and compositions for treating eye disorders
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US7993634B2 (en) 2004-04-30 2011-08-09 Allergan, Inc. Oil-in-oil emulsified polymeric implants containing a hypotensive lipid and related methods
US20060073208A1 (en) 2004-10-01 2006-04-06 Allergan, Inc. Cosmetic neurotoxin compositions and methods
CN103301094A (zh) * 2004-11-17 2013-09-18 乔安妮·麦克劳林 用于治疗蛋白聚集疾病的含鲨肌醇衍生物的组合物和方法
JP2007051090A (ja) * 2005-08-18 2007-03-01 Pharma Foods International Co Ltd 卵白ペプチドを有効成分として含有する血流改善剤
CA2626005A1 (en) * 2005-10-13 2007-10-25 Waratah Pharmaceuticals Inc. Inositol derivatives and their uses in the treatment of diseases characterized by abnormal protein folding or aggregation or amyloid formation, deposition, accumulation or persistence
US20070197452A1 (en) * 2006-02-17 2007-08-23 Mclaurin Joanne Treatment of amyloid-related diseases
EP1993523A4 (en) * 2006-02-17 2009-06-10 Joanne Mclaurin COMPOSITIONS AND METHODS FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
EP1996175A4 (en) * 2006-03-09 2009-06-10 Waratah Pharmaceuticals Inc CYCLOHEXAN POLYALKOHOL FORMULATION FOR THE TREATMENT OF PROTEIN AGGREGATION DISORDERS
WO2007134449A1 (en) * 2006-05-19 2007-11-29 Waratah Pharmaceuticals Inc. Screening methods for amyloid beta modulators
WO2007149567A2 (en) 2006-06-21 2007-12-27 Musc Foundation For Research Development Targeting complement factor h for treatment of diseases
US20100173960A1 (en) * 2006-09-21 2010-07-08 Antonio Cruz The Combination of a Cyclohexanehexol and a NSAID for the Treatment of Neurodegenerative Diseases
US20100292157A1 (en) * 2006-11-24 2010-11-18 Antonio Cruz Combination Treatments for Alzheimer's Disease and Similar Diseases
US8969415B2 (en) 2006-12-01 2015-03-03 Allergan, Inc. Intraocular drug delivery systems
HRP20130768T1 (en) * 2007-04-12 2013-10-25 Waratah Pharmaceuticals, Inc. Use of cyclohexanehexol derivatives in the treatment of ocular diseases
CA2683546A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Use of cyclohexanehexol derivatives in the treatment of .alpha.-synucleinopathies
US20110105626A1 (en) * 2007-04-12 2011-05-05 Mclaurin Joanne Use of cyclohexanehexol derivatives for the treatment of polyglutamine diseases
CA2683580A1 (en) * 2007-04-12 2008-10-23 Joanne Mclaurin Treatment of amyotrophic lateral sclerosis
US7632848B1 (en) * 2007-10-04 2009-12-15 Alan Brown Scott Medical treatment of muscles by exposure to anesthetic drugs
US8470337B2 (en) * 2008-03-13 2013-06-25 Allergan, Inc. Therapeutic treatments using botulinum neurotoxin
EP2334176A4 (en) * 2008-09-27 2012-05-02 Taraxos Inc TOPICAL FORMULATIONS FOR THE TREATMENT OF NERVE DISEASES
CA2740124A1 (en) * 2008-10-09 2010-04-15 Waratah Pharmaceuticals Inc. Use of scyllo-inositols for the treatment of macular degeneration-related disorders
US9815890B2 (en) 2010-06-22 2017-11-14 The Regents Of The University Of Colorado, A Body Corporate Antibodies to the C3d fragment of complement component 3
KR20130130694A (ko) * 2010-07-30 2013-12-02 알러간, 인코포레이티드 피부 재생을 위한 화합물과 방법
US20120142684A1 (en) * 2010-12-02 2012-06-07 Allergan, Inc. Compounds and methods for skin repair
BR112013025826A2 (pt) * 2011-04-07 2016-12-20 Sensimed Sa sistema de monitoramento de pelo menos um parâmetro biomecânico oftálmico e método
RU2692652C2 (ru) 2013-03-13 2019-06-25 Джензим Корпорейшн Слитые белки, содержащие связывающие pdgf и vegf части, и способы их применения
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
JP7097070B2 (ja) 2015-10-01 2022-07-07 ゴレイニ インコーポレイテッド クロライドチャネルの標的発現及びその使用方法
US9918994B2 (en) 2016-03-04 2018-03-20 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for muscle regeneration using prostaglandin E2
US11096993B2 (en) 2016-12-08 2021-08-24 Gary E. Borodic Method of treating macular degeneration using botulinum toxin-based pharmaceuticals
CA3061900A1 (en) * 2017-05-01 2018-11-08 The Board Of Supervisors Of Louisiana State University And Agriculturaand Mechanical College Compositions and methods for treating ocular pathologies
WO2018227138A1 (en) 2017-06-09 2018-12-13 The Board Of Trustees Of The Leland Stanford Junior University Compositions and methods for preventing or treating muscle conditions
CN112972444B (zh) * 2021-02-19 2022-07-26 中国医学科学院整形外科医院 美西律在制备治疗和/或预防面颈部皮肤皱纹的产品中的应用
CN113288784B (zh) * 2021-06-11 2023-03-31 中国人民解放军陆军军医大学第一附属医院 泪道冲洗收水装置
AU2024297654A1 (en) 2023-07-13 2026-01-22 Kriya Therapeutics, Inc. Complement pathway inhibitor fusions and methods of using the same

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6366122A (ja) * 1986-03-13 1988-03-24 ザ・トラステイ−ズ・オブ・コロンビア・ユニヴア−シテイ・イン・ザ・シテイ・オブ・ニユ−・ヨ−ク 緑内障の局所治療用組成物
WO2000028999A2 (en) * 1998-11-18 2000-05-25 Synchroneuron, Llc. Methods of treating tardive dyskinesia and other movement disorders
WO2001042191A1 (en) * 1999-12-08 2001-06-14 Warner-Lambert Company Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy
JP2001521500A (ja) * 1997-03-27 2001-11-06 アラーガン・セイルズ・インコーポレイテッド 緑内障に関連する視神経変性を防止する薬剤の製造におけるナトリウムチャンネル遮断剤の使用
JP2002521332A (ja) * 1998-07-21 2002-07-16 メルク エンド カムパニー インコーポレーテッド 高眼圧治療用眼薬組成物

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3545260A (en) * 1967-10-31 1970-12-08 Technicon Corp Means and method for detection of glaucoma
US3585849A (en) * 1968-10-09 1971-06-22 American Optical Corp Method and apparatus for measuring intraocular pressure
US3724263A (en) * 1970-09-29 1973-04-03 Bio Optronics Inc Electrical digital display tonometer
US3963019A (en) * 1974-11-25 1976-06-15 Quandt Robert S Ocular testing method and apparatus
US4186184A (en) * 1977-12-27 1980-01-29 Alza Corporation Selective administration of drug with ocular therapeutic system
US4305399A (en) * 1978-10-31 1981-12-15 The University Of Western Australia Miniature transducer
CH633952A5 (fr) * 1980-03-14 1983-01-14 Grounauer Pierre Alain Dispositif de mesure des potentiels electriques de l'oeil.
US4485820A (en) * 1982-05-10 1984-12-04 The Johns Hopkins University Method and apparatus for the continuous monitoring of hemoglobin saturation in the blood of premature infants
US4734275A (en) * 1983-08-19 1988-03-29 Research Corporation Anti-curare agents
JPS61321A (ja) * 1984-06-12 1986-01-06 株式会社トプコン 非接触式眼圧計
US4629424A (en) * 1984-08-30 1986-12-16 Integrated Ionics, Inc. Intraoral ambient sensing device
US4771792A (en) * 1985-02-19 1988-09-20 Seale Joseph B Non-invasive determination of mechanical characteristics in the body
US4628938A (en) * 1985-12-09 1986-12-16 Lee David A Continuous applanation tonometer
JPS63267331A (ja) * 1986-12-27 1988-11-04 Tokyo Optical Co Ltd 非接触式眼圧計
US5076274A (en) * 1987-02-18 1991-12-31 Canon Kabushiki Kaisha Non-contact tonometer
US5183044A (en) * 1987-06-30 1993-02-02 Kabushiki Kaisha Topcon Noncontact type tonometer
US4922913A (en) * 1987-11-12 1990-05-08 Waters Jr George E Intraocular pressure sensor
US4860755A (en) * 1988-02-08 1989-08-29 Erath-Young Instrument Company, Inc. Differential pressure applanation tonometer
US5165409A (en) * 1988-08-23 1992-11-24 Coan William M Tonometry apparatus
US4951671A (en) * 1988-08-23 1990-08-28 Coan William M Tonometry apparatus
US5005577A (en) * 1988-08-23 1991-04-09 Frenkel Ronald E P Intraocular lens pressure monitoring device
US5217015A (en) * 1990-06-08 1993-06-08 Kaye David B Pressure sensing device having transducer overlying and deforming eye
US5109852A (en) * 1990-06-08 1992-05-05 Kaye David B Method for sensing pressure in an object
US5342283A (en) * 1990-08-13 1994-08-30 Good Roger R Endocurietherapy
US5148807A (en) * 1990-08-28 1992-09-22 Ohio State University Non-contact tonometer
US5209231A (en) * 1990-11-02 1993-05-11 University Of Connecticut Optical glucose sensor apparatus and method
US5295495A (en) * 1991-05-13 1994-03-22 The Australian National University Glaucoma testing from observations of optokinetic nystagmus
US5251627A (en) * 1991-06-27 1993-10-12 Morris Donald E Non-invasive measurement of eyeball pressure using vibration
US5179953A (en) * 1991-08-27 1993-01-19 Jermik Systems, Ltd. Portable diurnal intraocular pressure recording system
US5972991A (en) * 1992-09-21 1999-10-26 Allergan Cyclopentane heptan(ene) oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5375595A (en) * 1993-03-17 1994-12-27 The Regents Of The University Of Calif. Apparatus and method for non-contact, acoustic resonance determination of intraocular pressure
US6350781B1 (en) * 1994-01-14 2002-02-26 Lee Shahinia, Jr. Method and analgesic preparations for sustained and extended corneal analgesia with subanesthetic concentrations of lidocaine
DK0866691T4 (da) * 1995-11-06 2005-06-06 Somerset Pharmaceuticals Inc Medikamenter til sublingual og bukkal administration af selegilin
US5830139A (en) * 1996-09-04 1998-11-03 Abreu; Marcio M. Tonometer system for measuring intraocular pressure by applanation and/or indentation
US6120460A (en) * 1996-09-04 2000-09-19 Abreu; Marcio Marc Method and apparatus for signal acquisition, processing and transmission for evaluation of bodily functions
US6544193B2 (en) * 1996-09-04 2003-04-08 Marcio Marc Abreu Noninvasive measurement of chemical substances
US6090847A (en) * 1997-11-21 2000-07-18 Allergan Sales, Inc. EP2 -receptor agonists as neuroprotective agents for the eye
AU2211700A (en) * 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Prostaglandin e agonists for treatment of glaucoma
US6306403B1 (en) * 2000-06-14 2001-10-23 Allergan Sales, Inc. Method for treating parkinson's disease with a botulinum toxin

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6366122A (ja) * 1986-03-13 1988-03-24 ザ・トラステイ−ズ・オブ・コロンビア・ユニヴア−シテイ・イン・ザ・シテイ・オブ・ニユ−・ヨ−ク 緑内障の局所治療用組成物
JP2001521500A (ja) * 1997-03-27 2001-11-06 アラーガン・セイルズ・インコーポレイテッド 緑内障に関連する視神経変性を防止する薬剤の製造におけるナトリウムチャンネル遮断剤の使用
JP2002521332A (ja) * 1998-07-21 2002-07-16 メルク エンド カムパニー インコーポレーテッド 高眼圧治療用眼薬組成物
WO2000028999A2 (en) * 1998-11-18 2000-05-25 Synchroneuron, Llc. Methods of treating tardive dyskinesia and other movement disorders
WO2001042191A1 (en) * 1999-12-08 2001-06-14 Warner-Lambert Company Branched chain amino acid-dependent aminotransferase inhibitors and their use in the treatment of diabetic retinopathy

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016518442A (ja) * 2013-05-15 2016-06-23 ボスティ トレーディング リミテッドＢｏｓｔｉ Ｔｒａｄｉｎｇ Ｌｔｄ． ボツリヌス神経毒を含む医薬組成物およびその使用
US10258673B2 (en) 2013-05-15 2019-04-16 Bosti Trading Ltd. Pharmaceutical composition comprising a botulinum neurotoxin and uses thereof
JP2020500938A (ja) * 2016-12-08 2020-01-16 ボロディック ゲイリー イーＢＯＲＯＤＩＣ，Ｇａｒｙ Ｅ． 黄斑変性症の新しい治療法
JP7716841B2 (ja) 2016-12-08 2025-08-01 ゲイリー イー ボロディック 黄斑変性症の新しい治療法

Also Published As

Publication number Publication date
CA2868648A1 (en) 2004-11-11
US20120282242A1 (en) 2012-11-08
EP1622589A4 (en) 2009-07-15
CA2523363C (en) 2015-02-10
EP1622589B1 (en) 2017-03-15
BR0318269A (pt) 2006-05-23
AU2003297684A1 (en) 2004-11-23
WO2004096183A1 (en) 2004-11-11
CA2523363A1 (en) 2004-11-11
US20040058313A1 (en) 2004-03-25
EP1622589A1 (en) 2006-02-08

Similar Documents

Publication Publication Date Title
CA2523363C (en) Compositions, targets, methods and devices for the therapy of ocular and periocular disorders
Casson Medical therapy for glaucoma: A review
Tseng et al. A randomized clinical trial of combined topical-intracameral anesthesia in cataract surgery
Tham et al. Phacoemulsification versus trabeculectomy in medically uncontrolled chronic angle-closure glaucoma without cataract
Lam et al. Efficacy and safety of immediate anterior chamber paracentesis in the treatment of acute primary angle-closure glaucoma: a pilot study
Christiansen et al. Mechanism of ocular hypotensive action of bimatoprost (Lumigan) in patients with ocular hypertension or glaucoma
Bardocci et al. Lidocaine 2% gel versus lidocaine 4% unpreserved drops for topical anesthesia in cataract surgery: a randomized controlled trial
KR100752821B1 (ko) 안과용 약물 전달 장치
Anderson et al. Comparison of preservative-free bupivacaine vs lidocaine for intracameral anesthesia: a randomized clinical trial and in vitro analysis
WO2010125416A1 (en) Drug delivery to the anterior and posterior segments of the eye
CN1382443A (zh) 钠离子通道阻断剂在制备用于局部神经麻醉或镇痛的药物中的应用
Zehetmayer et al. Topical anesthesia with pH-adjusted versus standard lidocaine 4% for clear corneal cataract surgery
Wiles et al. Control of intraocular pressure with apraclonidine hydrochloride after cataract extraction
Anders et al. Clinical and electrophysiologic results after intracameral lidocaine 1% anesthesia: a prospective randomized study
Kasetti et al. Preventing intraocular pressure increase after phacoemulsification and the role of perioperative apraclonidine
US20060067950A1 (en) Clostridial neurotoxins for use in wound healing
Pacella et al. Levobupivacaine vs. racemic bupivacaine in peribulbar anaesthesia: a randomized double blind study in ophthalmic surgery.
TW201414484A (zh) 利用神經毒素治療早洩之方法
RU2406470C1 (ru) Способ лечения вертикального нистагма
RU2211687C2 (ru) Способ лечения отслойки сетчатки
Irfan Minimal orbicularis myectomy: does it relieve spasms in benign essential blepharospasm?
Said et al. A comparative study of topical versus peribulbar anesthesia in phacoemulsification and implantation of foldable intraocular lens in cataract surgery
Simsek et al. Effects of 0.5% and 0.25% apraclonidine on postoperative intraocular hypertension after cataract extraction
Kartasasmita et al. The effectiveness of continuous intravitreal adrenaline as mydriatic adjuvant on pars plana vitrectomy in diabetic patient, a randomized clinical trial
Narayanaswamy et al. Randomized, controlled trial of a sustained delivery formulation of 5-fluorouracil for the treatment of failing blebs

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061208

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061208

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100208

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100428

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100511

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100809

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110725